Head-to-head · WeighScore
eMed vs myRocky
The verdict
eMed takes it — 57.4/100 to 51.4/100.
eMed grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. eMed is a digital health platform best known for at-home diagnostics that now runs a clinician-supported GLP-1 weight management program.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | eMed | myRocky |
|---|---|---|
| WeighScore | 57.4/100 | 51.4/100 |
| Grade | C | C |
| Scorecard rank | #398 | #487 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #398 · C
Strengths
- Prescribes FDA-approved branded GLP-1s (semaglutide and tirzepatide)
- At-home blood collection makes lab work convenient
- Clinician review and ongoing side-effect plus adherence support
- Works with CVS Caremark so eligible employees can buy through benefits
- Established digital health company with national scale
Where it loses points
- Distributed mainly via employers, with limited direct cash-pay access
- No public transparent monthly price for individuals
- Eligibility and subsidy depend on what the employer chooses to cover
- Best suited to workforces, not casual self-pay shoppers
Graded #487 · C
Strengths
- Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
- LegitScript Approved
- 42-state coverage with an 8-state expansion roadmap published
- Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription
Where it loses points
- Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
- Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
- Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
- Brand-only — no compounded option for cost-sensitive patients
- $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.